Publications by authors named "C O Blyth"
Objectives: PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.
Methods: Immunocompetent adults who had received two doses of BNT162b2 and any licensed COVID-19 booster at least three months prior were eligible.
Article Synopsis
- - Acute lower respiratory tract infection (ALRI) is a leading cause of child mortality globally, particularly affecting children in Papua New Guinea (PNG) due to Streptococcus pneumoniae.
- - Researchers conducted whole-exome sequencing on children in PNG and found a specific genetic variant (a single-nucleotide variant in the COQ6 gene) that is linked to higher morbidity from ALRI, with evidence from both human and mouse studies supporting its role.
- - The COQ6 variant plays a significant role in the biosynthesis of ubiquinone and impacts how the immune system responds to infections, highlighting a new genetic risk factor for pneumonia in PNG and the enzyme's involvement in inflammatory responses.
Article Synopsis
- COVID-19 vaccination in Australia began in February 2021, with initial vaccines requiring two doses; booster vaccinations are now being recommended to maintain immunity.
- The PICOBOO trial is a multi-site study that tests various COVID-19 booster vaccines in children and adults, looking at their effectiveness and safety across different vaccination histories and age groups.
- This adaptive trial structure allows for rapid adjustments to research elements, helping to explore the best approaches for combating COVID-19 variants and assessing new vaccines as they are introduced.
Background: Rising proportions of antimicrobial resistance (AMR) have been observed in both Staphylococcus aureus and Enterococcus spp. isolates.
Methods: The Australian Group on Antimicrobial Resistance (AGAR) surveillance program captures clinical and microbiological data of isolates detected in blood cultures across Australia.
Background: Gram-negative bloodstream infections are associated with significant morbidity and mortality in children. Increasing antimicrobial resistance (AMR) is reported globally, yet efforts to track pediatric AMR at a national level over time are lacking.
Methods: The Australian Group on Antimicrobial Resistance (AGAR) surveillance program captures clinical and microbiological data of isolates detected in blood cultures across Australia.